Skip to content

Effect of oral MgSo4 administration on plasma, inflammation marker, anti oxidant capacity, lysyl peroxidase, ox-LDL, LOX-1 levels and lipid profiles in atherosclerosis patients

Effect of oral MgSo4 administration on plasma, inflammation marker, anti oxidant capacity, lysyl peroxidase, SIRT1, p53, eNOSox-LDL, LOX-1 levels and lipid profiles in atherosclerosis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151028024756N3
Enrollment
100
Registered
2018-07-28
Start date
2018-05-22
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with high blood pressure and Hyperlipidemic with a small plaque in one of the coronary arteries. Atherosclerotic heart disease of native coronary artery without angina pectoris

Interventions

Intervention 1: Patients with CAD (moderate coronary artery disease) under 60% who will chose for intervention group after angiography. For all patients, the demographic information, the records of th

Sponsors

Bandare-abbas University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Moderate coronary artery disease<60 -2. Age of women and men should be more than 55 years and 45 years respectively. 3.Also people that are diabetic, hypertension, hyperlipidemia , smoker and insulin resistance will be entered in the study.

Exclusion criteria

Exclusion criteria: 1.Age of women be less than 55 years,2. pregnant women3. patients who are using magnesium and calcium containing supplements 4. patients who have experienced renal insufficiency (serum creatinine levels more than 1.3 mg/dl in women and more than 1.5 mg/dl in men). 5- elevated hepatic enzymes (more than 3 folds over normal values),recent infections (less than one month prior to study) and chronic inflammatory diseases, cerebrovascular accident(CVA), also cancer and drug sensetivity

Design outcomes

Primary

MeasureTime frame
Hypertension- Hyperlipidemic- Atherosclerosis. Timepoint: every three months. Method of measurement: Barometer device and appropriate kits.

Secondary

MeasureTime frame
Size of Atherosclerosis plaque. Timepoint: After one year. Method of measurement: With Angiography if patient satisfies.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNepton Soltani

Esfahan University of Medical Sciences

solnep2002@yahoo.com+98 31 3792 8019

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026